Proteomics-based Anticancer Drug Discovery and Development

被引:10
|
作者
Jain, K. K. [1 ]
机构
[1] Jain PharmaBiotech, CH-4057 Basel, Switzerland
关键词
Cancer; proteomics; drug discovery; drug targets; target validation; anticancer drugs;
D O I
10.1177/153303460200100403
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proteins are important targets for drug discovery and this applied to cancer as well because there is a defect in the protein machinery of the cell in malignancy. Proteomic technologies are now being integrated with genomic approaches for cancer drug discovery and target validation. Among the large number of proteomic technologies available for this purpose, the most important ones are 3-D protein structure determination, protein microarrays, laser capture microdissection and study of protein-protein and protein-drug interactions. Cancer biomarkers and several cell pathways are important drug targets. Several companies are involved in using proteomic technologies for drug discovery. Finally, proteomic approaches will play an important role in the discovery and development of personalized medicines.
引用
收藏
页码:231 / 236
页数:6
相关论文
共 50 条
  • [31] Proteomics-based approach for target discovery in Zika virus infection: abridged secondary publication
    Tun, H. M.
    Sanyal, S.
    HONG KONG MEDICAL JOURNAL, 2022, 28 : 29 - 32
  • [32] Proteomics-based discovery, verification, and validation of multiplex urine biomarkers for bladder cancer diagnosis
    Suh, Jungyo
    Han, Do Hyun
    Yoo, Sang Hyun
    Ku, Ja Hyun
    Kim, Hyeon Hoe
    Kwak, Cheol
    Jeong, Chang Wook
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 164 - 164
  • [33] Biomarker discovery by proteomics-based approaches for early detection and personalized medicine in colorectal cancer
    Corbo, Claudia
    Cevenini, Armando
    Salvatore, Francesco
    PROTEOMICS CLINICAL APPLICATIONS, 2017, 11 (5-6)
  • [34] Proteomics-based diagnostic peptide discovery for severe fever with thrombocytopenia syndrome virus in patients
    Sang-Yeop Lee
    Hayoung Lee
    Sung Ho Yun
    Edmond Changkyun Park
    Giwan Seo
    Hye-Yeon Kim
    Sangmi Jun
    Nam Hoon Kim
    Dongseob Tark
    Ju Yeon Lee
    Chang-Seop Lee
    Seung Il Kim
    Clinical Proteomics, 2022, 19
  • [35] Proteomics and Its Application in Biomarker Discovery and Drug Development
    He QingYu Chiu JenFu Department of Chemistry Open Laboratory of Chemical Biology of the Institute of Molecular Technology for Drug Discovery and Synthesis Institute of Molecular Biology University of Hong Kong
    合成化学, 2004, (S1) : 15 - 15
  • [36] Proteomics-Based Regression Model for Assessing the Development of Chronic Lymphocytic Leukemia
    Bakhtina, Varvara I.
    Veprintsev, Dmitry V.
    Zamay, Tatiana N.
    Demko, Irina V.
    Mironov, Gleb G.
    Berezovski, Maxim V.
    Petrova, Marina M.
    Kichkailo, Anna S.
    Glazyrin, Yury E.
    PROTEOMES, 2021, 9 (01) : 1 - 8
  • [37] Genomics and proteomics - The new millennium of drug discovery and development
    Cunningham, MJ
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 44 (01) : 291 - 300
  • [38] Proteomics in drug discovery
    Hewick, RM
    Lu, ZJ
    Wang, JH
    PROTEOME CHARACTERIZATION AND PROTEOMICS, 2003, 65 : 309 - 342
  • [39] Mass Spectrometry for Proteomics-Based Investigation
    Woods, Alisa G.
    Sokolowska, Izabela
    Wetie, Armand G. Ngounou
    Channaveerappa, Devika
    Dupree, Emmalyn J.
    Jayathirtha, Madhuri
    Aslebagh, Roshanak
    Wormwood, Kelly L.
    Darie, Costel C.
    ADVANCEMENTS OF MASS SPECTROMETRY IN BIOMEDICAL RESEARCH, 2ND EDITION, 2019, 1140 : 1 - 26
  • [40] Proteomics in drug discovery
    Wang, JH
    Hewick, RM
    DRUG DISCOVERY TODAY, 1999, 4 (03) : 129 - 133